Business Wire

MN-DIGI-INTERNATIONAL

17.1.2023 15:01:48 CET | Business Wire | Press release

Share
Digi International Launches Digi Containers to Improve Development, Operation, and Management of Custom Applications on Digi Cellular Routers

Digi International, (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) solutions, connectivity products, and services, today launched Digi Containers, a software service that enables the development and operation of custom applications on Digi cellular routers that run DAL OS. Digi Containers leverage the Digi Remote Manager® platform as the central portal for deploying and managing these applications.

The Digi Containers service helps developers take the fullest advantage of edge computing by providing the flexibility to deploy new services and apps while consolidating edge-processing hubs. These edge applications offer low latency and near-real-time responsiveness with the agility to respond to evolving use cases.

Through Digi Containers, developers employ Lightweight Linux Containers (LXCs) — essentially virtual machines (VMs) that share the physical device’s running kernel. This enables processes inside a container to run at native speed as if they are actually running directly on the host device. Since containers are lightweight and portable, they offer both security and flexibility. This enables developers to expand on the capabilities of Digi solutions to support specific needs.

As a value-added service for Digi cellular routers, Digi Containers enable users to upload, manage, deploy, and monitor container-based applications through Digi Remote Manager. This empowers companies to orchestrate and manage a complex series of containers in various structures and configurations. Digi Containers provide:

  • Portability – A containerized application can be deployed in private and public clouds. Companies gain flexibility because they can easily move workloads among environments and providers.
  • Scalability – Containers can scale horizontally (i.e., you can “clone” identical containers within the same cluster to expand capacity/throughput as needed). By running only what is needed, when needed, costs decrease significantly.
  • Increased security – By design, containers are inherently isolated. If one container is compromised, others won’t be affected.
  • Speed – Autonomy from the operating system gives greater control. You can start/stop a container in seconds. You achieve faster development and operational speed and a faster and smoother user experience.
  • Efficiency – Since a separate operating system isn’t required, containers require fewer resources than VMs. You can run several containers on a single server. Less hardware means lower costs and fewer points of failure.

“The launch of Digi Containers unlocks the power of edge computing on Digi cellular routers,” said Kinana Hussain, Vice President of Product Management. “By building in the embedded software environment on our devices, along with their inherent computational capabilities, developers can tap into a rich and growing set of features, capabilities, and services. These are all signed, vetted, and distributed as part of the Digi TrustFence® security framework to more easily create and support a variety of demanding containerized applications in the enterprise, industrial, and transportation markets.”

Digi Enhances Network Analytics Application

Recently, Digi also upgraded Digi intelliFlow® in Digi Remote Manager, further strengthening Digi’s edge-to-cloud software stack. Digi intelliFlow provides a graphical visualization of network application data, focusing on the top 10 users or top 10 destinations. This intuitive representation of network activity allows organizations to update settings on Digi routers or tailor the network to the site’s needs. Digi intelliFlow provides recent data and a historical reference to keep networks running smoothly. intelliFlow addresses excessive data usage with custom alarms that alert administrators when data limits are approaching.

“Our long-term vision is to enable a full suite of market vertical-specific value-added services that leverage our robust edge-to-cloud software stack to help our customers maximize their IoT investments while focusing on their core business,” said Hussain.

About Digi International

Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005154/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye